• LAST PRICE
    2.9000
  • TODAY'S CHANGE (%)
    Trending Up0.3400 (13.2813%)
  • Bid / Lots
    2.7300/ 1
  • Ask / Lots
    2.9300/ 5
  • Open / Previous Close
    2.5100 / 2.5600
  • Day Range
    Low 2.5001
    High 2.9000
  • 52 Week Range
    Low 2.0000
    High 13.3050
  • Volume
    80,800
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.56
TimeVolumeCYCC
09:32 ET8372.51
10:13 ET1002.6199
11:02 ET9532.6
11:03 ET1002.58
11:18 ET15002.5001
11:27 ET3142.55
11:30 ET12662.55
11:36 ET1902.6325
11:56 ET80002.6499
12:21 ET19002.62
01:09 ET33432.6297
01:11 ET3002.6
01:22 ET6972.6
01:24 ET5002.6172
01:27 ET1002.6299
01:29 ET53102.7399
01:31 ET62882.71
01:38 ET59612.7899
01:40 ET16162.766
01:44 ET63442.785
01:45 ET6272.8499
01:47 ET2002.7759
01:51 ET2282.85
01:58 ET2252.8001
02:02 ET1002.82
02:05 ET19002.85
02:07 ET2002.8567
02:14 ET9262.83
02:18 ET1002.8
02:25 ET10002.789
02:32 ET4002.75
02:43 ET1152.8272
02:59 ET89442.9
03:08 ET3412.8866
03:10 ET9742.88
03:12 ET80002.8501
03:24 ET3002.8101
03:28 ET10002.89
03:37 ET4002.87
03:44 ET4002.87
03:51 ET5502.85
03:53 ET1002.89
03:57 ET6802.89
04:00 ET11592.9
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCYCC
Cyclacel Pharmaceuticals Inc
3.8M
-0.1x
---
United StatesCING
Cingulate Inc
3.8M
0.0x
---
United StatesBPTH
Bio Path Holdings Inc
3.7M
-0.1x
---
United StatesKTRA
Kintara Therapeutics Inc
3.9M
0.0x
---
United StatesCPMV
Mosaic Immunoengineering Inc
3.6M
-2.9x
---
United StatesAXIM
Axim Biotechnologies Inc
3.7M
-0.5x
---
As of 2024-03-03

Company Information

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in solid tumors and hematological malignancies. The Company's Mitosis Regulation program includes Plogosertib, which is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in acute leukemias and solid tumors.

Contact Information

Headquarters
200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
Phone
908-517-7330
Fax
866-271-3466

Executives

Independent Chairman of the Board
Christopher Henney
President, Chief Executive Officer, Director
Spiro Rombotis
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Paul Mcbarron
Interim Chief Medical Officer, Director
Brian Schwartz
Independent Director
Samuel Barker

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.8M
Revenue (TTM)
$389.0K
Shares Outstanding
1.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.55
EPS
$-29.70
Book Value
$32.53
P/E Ratio
-0.1x
Price/Sales (TTM)
9.8
Price/Cash Flow (TTM)
---
Operating Margin
-7,439.08%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.